JP2010529128A - レット症候群および他の障害の処置 - Google Patents

レット症候群および他の障害の処置 Download PDF

Info

Publication number
JP2010529128A
JP2010529128A JP2010511198A JP2010511198A JP2010529128A JP 2010529128 A JP2010529128 A JP 2010529128A JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010529128 A JP2010529128 A JP 2010529128A
Authority
JP
Japan
Prior art keywords
igf
igf1
administered
pro
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010511198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529128A5 (cg-RX-API-DMAC7.html
Inventor
サー，ムリガンカ
トロペア，ダニエラ
ジアコメッティ，エマニュエル
イェーニッシュ，ルドルフ
ウィルソン，ネイサン，アール．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2010529128A publication Critical patent/JP2010529128A/ja
Publication of JP2010529128A5 publication Critical patent/JP2010529128A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2010511198A 2007-06-08 2008-06-06 レット症候群および他の障害の処置 Pending JP2010529128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93373807P 2007-06-08 2007-06-08
PCT/US2008/007107 WO2008153929A1 (en) 2007-06-08 2008-06-06 Igf for the treatment of rett syndrome and synaptic disorders

Publications (2)

Publication Number Publication Date
JP2010529128A true JP2010529128A (ja) 2010-08-26
JP2010529128A5 JP2010529128A5 (cg-RX-API-DMAC7.html) 2011-07-21

Family

ID=39891784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511198A Pending JP2010529128A (ja) 2007-06-08 2008-06-06 レット症候群および他の障害の処置

Country Status (8)

Country Link
US (2) US7994127B2 (cg-RX-API-DMAC7.html)
EP (1) EP2164509A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529128A (cg-RX-API-DMAC7.html)
CN (1) CN101820896A (cg-RX-API-DMAC7.html)
AU (1) AU2008262387A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812768A2 (cg-RX-API-DMAC7.html)
CA (1) CA2689549A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008153929A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) * 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
AU2007238608A1 (en) * 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EP2387611A4 (en) 2009-01-16 2012-08-15 Massachusetts Inst Technology DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS
EP2571515B1 (en) * 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
AU2012236150B2 (en) * 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2013016223A2 (en) * 2011-07-22 2013-01-31 The University Of Chicago Treatments for migraine and related disorders
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
ES2495266B8 (es) * 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CA2962406A1 (en) 2014-09-25 2016-03-31 Cold Spring Harbor Laboratory Treatment of rett syndrome
WO2017132127A1 (en) 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
CN108187031A (zh) * 2018-02-11 2018-06-22 中国人民解放军第四军医大学 rhIGF1在制备治疗脆性X综合征药物中的应用
US12324827B2 (en) 2019-09-09 2025-06-10 The University Of Chicago Combination therapy for the treatment of migraines
US20230312643A1 (en) * 2020-09-08 2023-10-05 Sunmarine Biotech Peptide derivative with collagenase inhibitory activity, and use thereof
WO2022165250A1 (en) * 2021-01-28 2022-08-04 University Of Florida Research Foundation, Incorporated Treating disorders associated with dyrk1a dysfunction

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
WO1995017204A1 (en) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1109572A4 (en) * 1998-09-03 2004-11-24 Neuronz Ltd NEUROPROTECTION
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
WO2002057241A1 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2002056873A2 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
EP1401808B1 (en) * 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7863304B2 (en) * 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
EP2274978B1 (en) * 2003-09-12 2015-05-20 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
US20070224165A1 (en) * 2003-10-23 2007-09-27 Neuren Pharmaceuticals Limited Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
JP2008511838A (ja) * 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
KR20060040550A (ko) * 2004-11-05 2006-05-10 마루이시세이야쿠가부시키가이샤 인슐린유사 성장인자-1 분비촉진제
JP2008545752A (ja) 2005-06-02 2008-12-18 テルシカ インコーポレーティッド 成長障害を処置するための方法
AU2007238608A1 (en) * 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013009128; ＮＡＴＵＲＥ　ＮＥＵＲＯＳＣＩＥＮＣＥ ＶＯＬ．９，　ＮＯ．５, 200605, Ｐ．６６０-６６８ *
JPN6013009131; ＣＨＥＭＯＴＨＥＲＡＰＹ ＶＯＬ．５２, 2006, Ｐ．２７９-２８１ *
JPN6013009132; ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ＶＯＬ．１５, 2005, Ｐ．２２７９-２２８３ *
JPN6013009134; ＡＣＴＡ　ＰＡＥＤＩＡＴＲ． ＶＯＬ．９０, 2001, Ｐ．１２５７-１２６１ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) * 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016210808A (ja) * 2011-01-27 2016-12-15 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2018138606A (ja) * 2011-01-27 2018-09-06 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤

Also Published As

Publication number Publication date
US20120177630A1 (en) 2012-07-12
EP2164509A1 (en) 2010-03-24
WO2008153929A1 (en) 2008-12-18
CA2689549A1 (en) 2008-12-18
AU2008262387A1 (en) 2008-12-18
BRPI0812768A2 (pt) 2014-12-02
US7994127B2 (en) 2011-08-09
CN101820896A (zh) 2010-09-01
US20090099077A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
JP2010529128A (ja) レット症候群および他の障害の処置
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
US20230381175A1 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
KR20160078950A (ko) 신경퇴행성 장애
EA006860B1 (ru) Композиции и способы модулирования гемиканалов коннексина
US12421280B2 (en) Insulin like growth factor binding protein bioactive peptide fragments
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
RU2491955C2 (ru) Активные растворимые изоформы нейрегулина, несущие посттрансляционные модификации
EP3448388B1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
US12582616B2 (en) Molecular targets for modulation of dissociative and associative states
RU2655811C2 (ru) Терапевтическое средство для бокового амиотрофического склероза
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
US20240189395A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
JP2021522283A (ja) 分子ピンセットによるリポフスチンの凝集の阻害
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
US20180326014A1 (en) Pharmaceutical formulations for the treatment of diabetes
JP2022104448A (ja) 認知症治療薬
TWI781073B (zh) 正丁烯基苯酞的醫藥用途
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders
WO2025179292A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
KR20230051091A (ko) 에제티미브를 유효성분으로 포함하는 폐섬유증의 예방, 개선, 완화 또는 치료용 약학적 조성물
EA040799B1 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806